ADAM17 and non-small cell lung carcinoma: found that the ADAM17 inhibitor ZLDI-8 could inhibit the Notch pathway and EMT thereby significantly promoting apoptosis in chemotherapy-resistant NSCLC and inhibiting NSCLC invasion and metastasis (124).